Eurostars Project AD-AIM 7927 Alzinova AB

Important results from the project

Alzinova AB and QPS Austria have been running the Eurostars project AD-AIM, which aimed at evaluating a new vaccine and developing new models within Alzheimer´s disease. Alzinova´s goal has been to demonstrate efficacy in an animal model, to establish a vaccine production method, do preliminary toxicology, and gain insight into the molecular mechanisms underlying the disease. However, the toxicology package was exchanged for another work package during the course of the project.

Expected long term effects

The project has successfully established a large-scale method for production of the antigen and evaluated the vaccine in an animal model. Alzinova has also drafted a detailed preclinical development plan and generated new IP within the scope of this project. Furthermore, the effects of vaccinating against the disease-driving forms of amyloid-beta (´the oligomers´) has generated insight into how these contribute to disease.

Approach and implementation

QPS Austria has contributed with expertise and in-house models of Alzheimer´s disease, and Alzinova with its unique proprietary technology to stabilize disease-driving amyloid-beta peptides. The consortium has fruitfully been able to exploit the complementary expertise of each participant. During the course of the project it was realized that some work packages had to be changed. Nevertheless, the high flexibility of the consortium still enabled the project to be concluded within budget.